Sensorion SA
RFM
Company Profile
Business description
Sensorion SA is a France-based clinical-stage biotech company dedicated to developing therapies to restore, treat, and prevent hearing loss. The company's product is in phase 2a clinical development, SENS-401 (Arazasetron) in Sudden Sensorineural Hearing Loss (SSNHL). SENS-401 is being developed to treat cochlear pathologies. The Company does business in a single operating segment: conducting research and development to discover drugs to treat inner ear disorders with a view to their future marketing. The company's pipeline programs are SENS-401 SSNHL, SENS-401 CIO, GJB2-GT, GJB2-GT, SENS-401 Cochlear, and others.
Contact
375, rue du Professeur Joseph Blayac
Montpellier34080
FRAT: +33 467207730
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
57
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,453.50 | 31.80 | 0.38% |
| CAC 40 | 7,694.44 | 67.60 | 0.89% |
| DAX 40 | 23,352.69 | 236.73 | 1.02% |
| Dow JONES (US) | 41,368.45 | 254.48 | 0.62% |
| FTSE 100 | 8,531.61 | 27.72 | -0.32% |
| HKSE | 22,716.50 | 59.42 | -0.26% |
| NASDAQ | 17,928.14 | 189.98 | 1.07% |
| Nikkei 225 | 37,478.58 | 549.95 | 1.49% |
| NZX 50 Index | 12,635.46 | 168.43 | 1.35% |
| S&P 500 | 5,663.94 | 32.66 | 0.58% |
| S&P/ASX 200 | 8,224.40 | 32.70 | 0.40% |
| SSE Composite Index | 3,340.73 | 11.27 | -0.34% |